ClinicalTrials.gg
Active, not recruitingNCT04204616Updated Nov 12, 2025

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

A Phase 3 interventional study of Nemolizumab in Prurigo Nodularis, sponsored by Galderma R&D. Active, not recruiting at 164 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-12.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Prurigo with a site in United States — 4 open to participants now, 8 under way, 4 of them phase 3. Prurigo · United States.

Planned enrollment
Largest of 21
500 · median 140
Started
2021
with 2 others
Phase 3
10 of 23
1 open now
Registered
5th of 23
by date
Lead sponsor
5 of 23
Galderma R&D

Among the 23 studies in Prurigo with a site in United States, this one has the largest planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2021, is one of 10 in phase 3, and was the 5th registered.

Prurigo

38 studies on the registry are indexed under Prurigo; 10 are open to participants now.

Browse Prurigo studies →

Open to participants now

4 of the 23 studies in Prurigo with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Prurigo studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prurigo with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).

03

Conditions studied

  • Prurigo Nodularis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who may benefit from study participation in the opinion of the investigator and participated in a prior nemolizumab study for PN including: (a). Participants who completed the treatment period in a phase 3 pivotal study (NCT04501666 or NCT04501679) and enroll within 56 days OR (b). Participants who were previously randomized in the nemolizumab phase 2a PN study (NCT03181503) OR (c). Participants who completed through Week 24 of the phase 3b durability study (NCT05052983) or who exit the study due to relapse may be eligible to re-enter in the LTE study within 28 days of exiting the durability study (selected countries/ selected sites)
  • Female participants of (that is, fertile, following menarche and until becoming unless permanently sterile) must agree either to be strictly abstinent throughout the study and for 12 weeks after the last study drug injection, or to use an adequate and approved method of throughout the study and for 12 weeks after the last study drug injection
  • Participant willing and able to comply with all of the time commitments and procedural requirements of the clinical study protocol, including periodic weekly recordings by the participant using an electronic handheld device provided for this study
  • Understand and sign an form (ICF) before any procedure(s) are performed

Exclusion criteria

Exclusion Criteria:

  • Participants who, during their participation in a prior nemolizumab study, experienced an adverse event (AE) which in the opinion of the investigator could indicate that continued treatment with nemolizumab may present an unreasonable risk for the participant
  • Body weight \< 30 kg
  • Pregnant women (positive pregnancy test result at screening or baseline visit or re-entry Week R0 visit), breastfeeding women, or women planning a pregnancy during the clinical study
  • Any medical or psychological condition that may put the participant at significant risk according to the investigator's judgment, if he/she participates in the clinical study, or may interfere with study assessments (example, poor venous access or needle-phobia)
  • Planning or expected to have a major surgical procedure during the clinical study
  • Participants unwilling to refrain from using prohibited medications during the clinical study
  • History of alcohol or substance abuse within 6 months prior to the screening visit or re-entry Week R0 visit
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Nemolizumab

    Participants weighing less than (\<) 90kilogram (kg) will receive 30 milligram (mg) nemolizumab every 4 weeks (Q4W) and participants weighing greater than or equal to (\>=) 90 kg will receive 60 mg nemolizumab (two 30-mg injections) Q4W.

    Drug: Nemolizumab

Interventions

  • Nemolizumab 30 mg will be administered as subcutaneous (SC) injection.

    Also known as: CD14152

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs) by Severity

    Incidence of AEs including AEs of Special Interest (AESIs), Treatment Emergent AEs (TEAEs) and Serious AEs (SAEs) by severity as mild, moderate or severe will be reported. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with relevant investigational product. SAE is any untoward medical occurrence that at any dose may results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. TEAE is an AE that occurs on or after the first date of study drug(s) administration until the date of last study visit. An AESI is a noteworthy treatment-emergent event for the study drug that should be monitored closely and reported promptly.

    Time frame: Up to 192 weeks

Secondary outcomes

  1. Percentage of Participants with an Investigator Global Assessment (IGA) Success up to Week 184

    Percentage of participants with an IGA success (defined as IGA of 0 \[Clear\] or 1 \[Almost clear\]) up to Week 184 will be reported.

    Time frame: Up to Week 184

  2. Percentage of Participants with an Improvement of >=4 from Baseline in Peak Pruritus (PP) Numeric Rating Scale (NRS) up to Week 184

    Percentage of participants with an improvement of \>= 4 from baseline in PP NRS up to Week 184 will be reported. The PP NRS has a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

    Time frame: Baseline up to Week 184

  3. Percentage of Participants with Low Disease Activity State up to Week 184

    Percentage of participants with low disease activity state (that is, IGA less than or equal to \[\<=\]2) up to Week 184 will be reported.

    Time frame: Up to Week 184

  4. Percentage of Pruriginous Lesions with Excoriations/Crusts up (PAS item 5a) up to Week 184

    Prurigo Activity Score (PAS) will include a count of the number of lesions in a representative area and a calculated staging (stage 0 to stage 4) based on the percentage of lesions with excoriations/crusts and healed lesions compared to all lesions. PAS item 5a reflects the current itch/scratch activity. It is used to estimate what percentage of the pruriginous legions show excoriations/crusts. 100 percent (%) = All pruriginous lesions have excoriations/crusts. Percentage of pruriginous lesions with excoriations/crusts (PAS item 5a) up to Week 184 will be reported.

    Time frame: Up to Week 184

  5. Percentage of Healed Prurigo Lesions (PAS item 5b) up to Week 184

    PAS item 5b item reflects the stage of the prurigo. It is used to estimate what percentage of the pruriginous lesions have healed.100% = all pruriginous lesions have healed. Percentage of healed prurigo lesions (PAS item 5b) up to Week 184 will be reported.

    Time frame: Up to Week 184

  6. Change from Baseline in Number of Lesions in Representative Area (PAS item 4) up to Week 184

    Change from baseline in number of lesions in representative area (PAS item 4) up to Week 184 will be reported.

    Time frame: Baseline up to Week 184

  7. Percentage of Participants with PP NRS <2 up to Week 184

    Percentage of participants with PP NRS \<2 up to Week 184 will be reported. PP NRS is a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

    Time frame: Up to Week 184

  8. Percent Change from Baseline in PP NRS up to Week 184

    Percent change from baseline in PP NRS up to Week 184 will be reported. PP NRS is a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

    Time frame: Baseline up to Week 184

  9. Absolute Change from Baseline in PP NRS up to Week 184

    Absolute change from baseline in PP NRS up to Week 184 will be reported. PP NRS is a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

    Time frame: Baseline up to Week 184

  10. Percentage of Participants with Average Pruritus (AP) NRS <2 up to Week 52

    Percentage of participants with AP NRS less than (\<) 2 up to Week 52 will be reported. AP NRS has a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

    Time frame: Up to Week 52

  11. Percentage of Participants with an Improvement of >=4 from Baseline in AP NRS up to Week 52

    Percentage of participants with an improvement of \>=4 from baseline in AP NRS up to Week 52 will be reported. AP NRS has a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

    Time frame: Up to Week 52

  12. Percent Change from Baseline in AP NRS up to Week 52

    Percent change from baseline in AP NRS up to Week 52 will be reported. AP NRS has a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

    Time frame: Up to Week 52

  13. Absolute Change from Baseline in AP NRS up to Week 52

    Absolute change from baseline in AP NRS up to Week 52 will be reported. AP NRS has a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable".

    Time frame: Up to Week 52

  14. Percentage of Participants with an Improvement of >=4 from Baseline in Sleep Disturbance (SD) NRS up to Week 184

    Percentage of participants with an improvement of \>=4 from baseline in Sleep Disturbance (SD) NRS up to Week 184 will be reported. SD NRS has a scale of 0 to 10, with 0 being "no sleep loss related to the symptoms of my skin disease (prurigo nodularis)" and 10 being "I did not sleep at all due to the symptoms of my skin disease (prurigo nodularis)".

    Time frame: Up to Week 184

  15. Percent Change from Baseline in SD NRS up to Week 184

    Percent change from baseline in SD NRS up to Week 184 will be reported. SD NRS has a scale of 0 to 10, with 0 being "no sleep loss related to the symptoms of my skin disease (prurigo nodularis)" and 10 being "I did not sleep at all due to the symptoms of my skin disease (prurigo nodularis)".

    Time frame: Up to Week 184

  16. Absolute Change from Baseline in SD NRS up to Week 184

    Absolute change from baseline in SD NRS up to Week 184 will be reported. SD NRS has a scale of 0 to 10, with 0 being "no sleep loss related to the symptoms of my skin disease (prurigo nodularis)" and 10 being "I did not sleep at all due to the symptoms of my skin disease (prurigo nodularis)".

    Time frame: Up to Week 184

  17. Change from Baseline in Prurigo Nodularis (PN)-associated Pain Frequency up to Week 184

    Change from baseline in PN-associated pain frequency up to Week 184 will be reported. The pain frequency will be assessed on a scale of 0 to 5 where 0 = never, 1 = less than once a week, 2 = 1-2 days a week, 3 = 3-4 days a week, and 4 = 5-6 days a week.

    Time frame: Baseline up to Week 184

  18. Change from Baseline in PN-associated Pain Intensity up to Week 184

    Change from baseline in PN-associated pain intensity up to Week 184 will be reported. The pain intensity will be assessed on a scale of 0 to 10, with 0 being "no pain" and 10 being "the worst unbearable pain".

    Time frame: Baseline up to Week 184

  19. Percentage of Participants Reporting low Disease Activity Based on Patient Global Assessment of Disease (PGAD) up to Week 52

    Percentage of participants reporting low disease activity (clear, almost clear, or mild) based on Patient Global Assessment of Disease (PGAD) up to Week 52 to be reported.

    Time frame: Up to Week 52

  20. Percentage of Participants Satisfied with Study Treatment Based on Patient Global Assessment of Treatment (PGAT) up to Week 52

    Percentage of participants satisfied with study treatment (good, very good, or excellent) based on Patient Global Assessment of Treatment (PGAT) up to Week 52 will be reported.

    Time frame: Up to Week 52

  21. Percentage of Participants with a Change of >=4 from Baseline in Dermatology Life Quality Index (DLQI) up to Week 184

    Percentage of participants with a change of \>=4 from baseline in Dermatology Life Quality Index (DLQI) up to Week 184 will be reported. The DLQI is a validated 10-item questionnaire covering domains including symptoms/feelings, daily activities, leisure, work/school, personal relationships, and treatment. The participant will rate each question ranging from 0 (not at all) to 3 (very much). A higher total score indicates a poorer quality of life (QoL).

    Time frame: Baseline up to Week 184

  22. Change from Baseline in EuroQoL 5-Dimension (EQ-5D) up to Week 184

    Change from baseline in EuroQoL 5-Dimension (EQ-5D) up to Week 184 will be reported. The EQ-5D instrument is a validated questionnaire, completed by the participant that consists of 2 parts. The first part consists of 5 multiple choice QoL questions and the second is a 100 point Visual Analog Scale (VAS) with 0 being "Worst imaginable health state" and 100 being "Best imaginable health state".

    Time frame: Baseline up to Week 184

  23. Time to Permanent Study Drug Discontinuation

    Time frame: Baseline to 184 weeks

  24. Time to Rescue Therapy

    Time frame: Baseline to 184 weeks

  25. Percentage of Participants Receiving Any Rescue Treatment by Rescue Treatment

    Time frame: Baseline up to 184 weeks

07

Study locations

164 sites
  • Galderma Investigational Site
    Birmingham, Alabama 35233, United States
  • Galderma Investigational Site
    Birmingham, Alabama 35244, United States
  • Galderma Investigational Site
    Fountain Valley, California 92708, United States
  • Galderma Investigational Site
    Los Angeles, California 90045, United States
  • Galderma Investigational Site
    San Diego, California 92123, United States
  • Galderma Investigational Site
    San Diego, California 92130, United States
  • Galderma Investigational Site
    Santa Monica, California 94404, United States
  • Galderma Investigational Site
    Washington D.C., District of Columbia 20037, United States
  • Galderma Investigational Site
    Aventura, Florida 33180, United States
  • Galderma Investigational Site
    Delray Beach, Florida 33484, United States
  • Galderma Investigational Site
    Hollywood, Florida 33021, United States
  • Galderma Investigational Site
    Largo, Florida 33770, United States
  • Galderma Investigational Site
    Miami, Florida 33125, United States
  • Galderma Investigational Site
    Miami, Florida 33136, United States
  • Galderma Investigational Site
    North Miami Beach, Florida 33162, United States
  • Galderma Investigational Site
    Ormond Beach, Florida 32174, United States
  • Galderma Investigational Site
    Pembroke Pines, Florida 33028, United States
  • Galderma Investigational Site
    Tampa, Florida 33607, United States
  • Galderma Investigational Galderma Investigational Site
    Columbus, Georgia 31904, United States
  • Galderma Investigational Site
    Macon, Georgia 31217, United States
  • Galderma Investigational Site
    Newnan, Georgia 30263, United States
  • Galderma Investigational Site
    Chicago, Illinois 60602, United States
  • Galderma Investigational Galderma Investigational Site
    Chicago, Illinois 60613, United States
  • Galderma I Galderma Investigational Site
    Lake Bluff, Illinois 60044, United States
  • Galderma Investigational Site
    Indianapolis, Indiana 46250, United States
  • Galderma Investigational Site
    Topeka, Kansas 66614, United States
  • Galderma Investigational Site
    Louisville, Kentucky 40241, United States
  • Galderma Investigational Site
    Baltimore, Maryland 21231, United States
  • Galderma Investigational Site
    Boston, Massachusetts 02111, United States
  • Galderma Investigational Site
    Ann Arbor, Michigan 48109, United States
  • Galderma Investigational Site
    Saint Joseph, Michigan 49085, United States
  • Galderma Investigational Site
    Saint Joseph, Missouri 64506, United States
  • Galderma Investigational Site
    St Louis, Missouri 63110, United States
  • Galderma Investigational Site
    Henderson, Nevada 89052, United States
  • Galderma Investigational Site
    New York, New York 10021, United States
  • Galderma Investigational Galderma Investigational Site
    New York, New York 10065, United States
  • Galderma Investigational Site
    High Point, North Carolina 27262, United States
  • Galderma Investigational Site
    Raleigh, North Carolina 27617, United States
  • Galderma Investigational Site
    Winston-Salem, North Carolina 27104, United States
  • Galderma Investigational Site
    Cincinnati, Ohio 45627, United States
  • Galderma Investigational Site
    Cleveland, Ohio 44106, United States
  • Galderma Investigational Site
    Dublin, Ohio 43016, United States
  • Galderma Investigational Site
    Philadelphia, Pennsylvania 19103, United States
  • Galderma Investigational Site
    Anderson, South Carolina 29621, United States
  • Galderma Investigational Site
    Knoxville, Tennessee 37909, United States
  • Galderma Investigational Site
    Murfreesboro, Tennessee 37130, United States
  • Galderma Investigational Galderma Investigational Site
    Austin, Texas 78738, United States
  • Galderma Investigational Site
    Dallas, Texas 75230, United States
  • Galderma Investigational Site
    Dripping Springs, Texas 78620, United States
  • Galderma Investigational Site
    Houston, Texas 77401, United States
  • Galderma Investigational Site
    Pflugerville, Texas 78660, United States
  • Galderma Investigational Site
    Webster, Texas 77004, United States
  • Galderma Investigational Site
    Salt Lake City, Utah 84117, United States
  • Galderma Investigational Galderma Investigational Site
    Springville, Utah 84663, United States
  • Galderma Investigational Site
    Fairfax, Virginia 22031, United States
  • Galderma Investigational Site
    Lynchburg, Virginia 24501, United States
  • Galderma Investigational Site
    Morgantown, West Virginia 26505, United States
  • Galderma Investigational Site
    Graz, 8036, Austria
  • Galderma Investigational Site
    Linz, 4020, Austria
  • Galderma Investigational Site
    Vienna, 1220, Austria
  • Galderma Investigational Site
    Brussels, 1200, Belgium
  • Galderma Investigational Site
    Ghent, 9000, Belgium
  • Galderma Investigational Site
    Jette, 1090, Belgium
  • Galderma Investigational Site
    Leuven, 3000, Belgium
  • Galderma Investigational Site
    Liège, 4000, Belgium
  • Galderma Investigational Site
    Calgary, AL T3E OB2, Canada
  • Galderma Investigational Site
    London, Ontario N6A 3H7, Canada
  • Galderma Investigational Site
    North York, Ontario M2M 4J5, Canada
  • Galderma Investigational Site
    Saskatoon, Saskatchewan S7K OH6, Canada
  • Galderma Investigational Site
    Calgary, T2G 1B1, Canada
  • Galderma Investigational Site
    London, N6H 5L5, Canada
  • Galderma Investigational Site
    Markham, L3P 1X2, Canada
  • Galderma Investigational Site
    Toronto, M3H 5Y8, Canada
  • Galderma Investigational Site
    Aarhus, 8200, Denmark
  • Galderma Investigational Site
    Hellerup, 2900, Denmark
  • Galderma Investigational Site
    Bordeaux, 33000, France
  • Galderma Investigational Site
    Brest, 29200, France
  • Galderma Investigational Site
    Nantes, 44093, France
  • Galderma Investigational Site
    Nice, 06202, France
  • Galderma Investigational Site
    Paris, 75020, France
  • Galderma Investigational Site
    Paris, 75475, France
  • Galderma Investigational Site
    Pierre-Bénite, 69495, France
  • Galderma Investigational Site
    Rouen, 76000, France
  • Galderma Investigational Site
    Saint-Etienne, 42055, France
  • Galderma Investigational Site
    Toulouse, 31000, France
  • Galderma Investigational Site
    Valence, 26953, France
  • Galderma Investigational Site
    Aachen, 52074, Germany
  • Galderma Investigational Site
    Augsburg, 86179, Germany
  • Galderma Investigational Site
    Bad Bentheim, 48455, Germany
  • Galderme Investigational Site
    Berlin, 10117, Germany
  • Galderma Investigational Site
    Bonn, 53105, Germany
  • Galderma Investigational Site
    Darmstadt, 64297, Germany
  • Galderma Investigational Site
    Dresden, 01307, Germany
  • Galderma Investigational Site
    Düsseldorf, 40225, Germany
  • Galderma Investigational Site
    Eppendorf, 20246, Germany
  • Galderma Investigational Site
    Göttingen, 37075, Germany
  • Galderma Investigational Site
    Halle, 06120, Germany
  • Galderma Investigational Site
    Hamburg, 20251, Germany
  • Galderma Investigational Site
    Heidelberg, 69115, Germany
  • Galderma Investigational Site
    Kiel, 24105, Germany

Showing the first 100 of 164 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Legat FJ, Kwatra SG, Reich A, Boulinguez S, Tsianakas A, Sauder M, Barbarot S, Szepietowski JC, Conrad C, Pink AE, Weisshaar E, Misery L, Metz M, Laquer VT, Sivamani RK, Yosipovitch G, Thaci D, Skov L, Chen X, Noda A, Jabbar-Lopez ZK, Piketty C, Stander S. Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis. J Eur Acad Dermatol Venereol. 2026 Jul;40(7):1195-1207. doi: 10.1111/jdv.70266. Epub 2025 Dec 17. PubMed 41405008 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2021 (actual). Primary completion is estimated for Oct 2026, 69 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2019
First posted
Dec 19, 2019
StartActual
Jan 11, 2021
Primary completionEst.
Oct 26, 2026
CompletionEst.
Oct 26, 2026
Last update
Nov 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04204616
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Dec 19, 2019
Start date
Jan 11, 2021
Primary completion
Oct 26, 2026 (estimated)
Completion
Oct 26, 2026 (estimated)
Last update
Nov 12, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nemolizumab

Start the discussion